See more : European Biotech Acquisition Corp. (EBACW) Income Statement Analysis – Financial Results
Complete financial analysis of Ludwig Enterprises, Inc. (LUDG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ludwig Enterprises, Inc., a leading company in the Broadcasting industry within the Communication Services sector.
You may be interested
- XMReality AB (publ) (XMMRF) Income Statement Analysis – Financial Results
- Medivir AB (publ) (MVIR-B.ST) Income Statement Analysis – Financial Results
- GeoJunxion N.V. (GOJXN.AS) Income Statement Analysis – Financial Results
- Pure Hydrogen Corporation Limited (PH2.AX) Income Statement Analysis – Financial Results
- Colipays, S.A. (MLCLP.PA) Income Statement Analysis – Financial Results
Ludwig Enterprises, Inc. (LUDG)
About Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc. operates as a broadcasting company in the United States. It offers The One radio receiver, a mobile, multi-channel, and multi-purposed digital 2-way communication device that offers 50 channels of digital programming, including Filipino, Pakistani, Hebrew, Chinese, Greek, Russian, and other; and provides English programming, old time radio shows, news, audio books, educational and religious programming, and techno and classical music. The company was founded in 1988 and is based in Pompano Beach, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 125.93K | 0.00 | 0.00 | 0.00 | 0.00 | 135.24K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 155.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -29.32K | 0.00 | 0.00 | 0.00 | 0.00 | 135.24K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | -23.28% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 436.40K | 113.25K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 881.89K | 447.26K | 45.72K | 28.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 135.58K | 79.93 | 45.68K | 299.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.02M | 447.26K | 45.72K | 4.80K | 78.44K | 5.02K | 5.86K | 5.16K | 2.54K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.45M | 560.51K | 45.72K | 4.80K | 78.44K | 5.02K | 5.86K | 5.16K | 2.54K |
| Cost & Expenses | 1.45M | 560.51K | 45.72K | 160.06K | 78.44K | 5.02K | 5.86K | 5.16K | 2.54K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 485.23K | 449.12K | 91.74K | 20.11K | 6.70K | 5.54K | 4.40K | 0.00 | 0.00 |
| Depreciation & Amortization | -517.45K | 560.51K | 45.72K | 28.81K | 171.86K | 161.14K | 52.52K | 0.00 | 0.00 |
| EBITDA | -1.97M | 0.00 | 0.00 | -5.32K | -78.44K | -5.02K | -5.86K | -5.16K | 132.70K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -27.09% | 0.00% | 0.00% | 0.00% | 0.00% | 98.12% |
| Operating Income | -1.45M | -560.50K | -45.72K | -34.12K | -78.44K | -5.02K | -5.86K | -5.16K | 132.70K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -27.09% | 0.00% | 0.00% | 0.00% | 0.00% | 98.12% |
| Total Other Income/Expenses | -1.00M | -404.65K | -91.75K | -20.11K | -6.70K | -5.54K | -4.40K | 137.86K | -2.00 |
| Income Before Tax | -2.46M | -965.15K | -137.47K | -54.23K | -85.14K | -10.56K | -10.26K | 132.70K | 132.70K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -43.06% | 0.00% | 0.00% | 0.00% | 0.00% | 98.12% |
| Income Tax Expense | 0.00 | -560.51 | -45.72 | -28.81 | -171.86K | -161.14K | -52.52K | 0.00 | 0.00 |
| Net Income | -2.46M | -965.15K | -137.47K | -54.23K | -85.14K | -10.56K | -10.26K | 132.70K | 132.70K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -43.06% | 0.00% | 0.00% | 0.00% | 0.00% | 98.12% |
| EPS | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 286.56M | 313.74M | 331.21M | 335.89M | 335.39M | 303.19M | 303.19M | 341.86M | 341.86M |
| Weighted Avg Shares Out (Dil) | 286.56M | 313.74M | 331.21M | 335.89M | 335.39M | 303.19M | 303.19M | 341.86M | 341.86M |
Ludwig Enterprises Begins PCR Validation Test Process
Final step before the full launch of breast cancer screening program, Revealia™ SPARKS, NV / ACCESSWIRE / November 7, 2024 / Ludwig Enterprises, Inc. (OTC PINK:LUDG), a leading USA-based biotechnology company (the "Company"), has retained an independent lab in Florida...
Ludwig Enterprises Files Provisional Patent for Revolutionary Cancer Screening Algorithm, Plans 2024 Launch as Revealia(TM)
SPARKS, NV / ACCESSWIRE / October 24, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG), a leading USA-based biotechnology company, has filed a provisional patent for its breakthrough cancer detection method titled "mRNAs Differentially Expressed in Cancer." The company's latest innovation,...
CORRECTING AND REPLACING: Ludwig Enterprises Inc. Announces AI-Powered Cancer Screening Technology
This press release replaces the release issued today at 9:15am EDT. Revolutionary AI-driven cheek swab test poised to transform early cancer detection with continuously improving accuracy.
Ludwig Enterprises Inc. Announces AI-Powered Cancer Screening Technology
Revolutionary AI-driven cheek swab test poised to transform early cancer detection with continuously improving accuracy. Revealia™: A Breakthrough in Cancer Detection through Advanced AI and Machine Learning SPARKS, NV / ACCESSWIRE / September 24, 2024 / Ludwig Enterprises, Inc. (OTC...
Ludwig Announces Acquisition of Intellectual Property and Patent
SPARKS, NV / ACCESSWIRE / September 17, 2024 / Ludwig Enterprises, Inc., (OTC PINK:LUDG), a USA-based biotechnology company, is pleased to announce it has acquired all the intellectual property and patent of the mRNA Neuro Panel and Serotonin Assay, along...
Nova Mentis Assigns Intellectual Property
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company") is pleased to announce it has entered into an intellectual property conveyance agreement (the "Agreement") with...
Ludwig Announces Substantial Corporate Initiatives
Revealia™, the world's most convenient cancer screening test, to launch in 2024 SPARKS, NV / ACCESSWIRE / August 14, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG), a USA-based biotechnology company, is pleased to announce its corporate vision for the next...
Ludwig Enterprises Files Provisional Patent on mRNA Genetic Screening Signals in Breast, Colon and Bladder Cancer
SPARKS, NV / ACCESSWIRE / July 9, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG), a USA based biotechnology company is pleased to announce that the company has filed a provisional patent titled "mRNAs DIFFERENTIALLY EXPRESSED IN COLORECTAL CANCER, BREAST CANCER,...
Ludwig Enterprises Inc (OTC:LUDG) Funds Incurable Brain Cancer Study
SPARKS, NV / ACCESSWIRE / March 27, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG): A US-based biotechnology company is pleased to announce that its subsidiary Exousia AI is funding a preclinical study on Glioblastoma (GBM), an incurable brain cancer. The...
Ludwig Enterprises Inc (OTC:LUDG) Enters Booming Artificial Intelligence Cancer Screening Market with its Non-Invasive Cancer Diagnostics Testing Kit, launching within 2024
SPARKS, Nev., March 19, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc, (OTC: LUDG): A US-based biotechnology company is pleased to announce it has entered the booming artificial intelligence cancer screening market. The company, with its wholly owned subsidiary M-RNA for...
Source: https://incomestatements.info
Category: Stock Reports